Skip to content

Search

Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

To determine the incidence, serotype distribution and clinical outcomes of invasive pneumococcal disease in children with acute lymphoblastic leukaemia following widespread use of pneumococcal conjugate vaccines.

Respiratory Syncytial Virus Transmission in Closed Community Settings That Include Children: A Systematic Review and Meta-Analysis

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections in children and is predominantly acquired and spread in community settings such as households and early childhood education centres. This review aims to synthesise the available evidence on RSV transmission in closed community settings that include children, with a focus on secondary attack rates.

A randomized prospective study of neonatal hepatitis B vaccine immunogenicity in The Gambia and Papua New Guinea

Protection of newborns from infection can be achieved through maternal or vaccine-induced antibodies, but the factors influencing vaccine protection (correlate of protection) and subsequent infant immunity remain insufficiently understood. Further investigation is essential to optimize early-life vaccination strategies.

The impact of a vancomycin intervention on vancomycin-associated nephrotoxicity in children: a quality improvement initiative

Vancomycin is first-line treatment for methicillin-resistant Staphylococcus aureus infections. However, despite guideline recommendations, there is no evidence that targeting vancomycin trough concentrations of ≥15 mg/L in children confers clinical benefit and is associated with vancomycin-associated nephrotoxicity. 

Cost constraints in supporting the Healthy Living Practices in remote Aboriginal communities: A Western Australian perspective

The Healthy Living Practices (HLPs) outline nine essential guidelines for maintaining health in remote Aboriginal communities, yet high costs and poor availability make them financially out of reach for many families. We assessed the cost and availability of essential goods required to support the HLPs in eight remote Kimberley community stores, recording prices during three visits in 2022 as part of the SToP (See, Treat, Prevent) Skin Sores and Scabies Trial, and retrospectively comparing these (inflation-adjusted) with Perth and Broome prices in 2024. 

Population-specific heterogeneity in ontogeny of the broadly-conserved blood transcriptional program during the first week of life

Previous research has shown that immune development during the first week of life, i.e. ontogeny, is progressive, consistent and robust, involving large numbers of differentially expressed genes at each sampled time point.

Translating the Eczema Bathing Study: why context and infection burden matter

Asha Jacinta Bernadette Bowen Walton Ricciardo BA MBBS DCH FRACP PhD GAICD FAHMS OAM MBBS (hon) DCH FACD Head, Healthy Skin and ARF Prevention

Prospective longitudinal study of respiratory syncytial virus and other respiratory viruses in children <5 years in community settings in metropolitan western Australia: the PATROL study

Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in young children. Since 2021, RSV has been a notifiable disease in Australia. However, current surveillance systems focus on hospitalised RSV, with limited surveillance at a community level through primary care clinics. This approach only captures RSV requiring hospitalisation. Less severe illnesses, while not captured, may have significant social and economic impacts including the associated cost of care and absenteeism. The aim of this study is to establish an understanding of the broader burden of RSV in young children in a community setting.

Stakeholders Want a Menu of Choices: Findings from a Consultation Workshop on Improving Access to Secondary Prophylaxis of Rheumatic Fever and Rheumatic Heart Disease

Intramuscular (IM) injection of benzathine benzylpenicillin G (BPG) forms the cornerstone of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) secondary prophylaxis. BPG is available as either a low-cost powdered formulation or a costlier pre-filled suspension. Most of the global RHD burden lies in low- and middle-income countries, which rely on the powdered formulation.